Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasm Metastasis 1Multiple Myeloma 1Cancer Pain 1

Interventions

Oxycodone 5Morphine 5nabiximols 4Naloxone 2Fentanyl 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1naloxegol 1incobotulinumtoxinA 1Water 1Transcranial Direct Current Stimulation 1Tapentadol 1Sodium Bicarbonate 1Methadone 1Lidocaine 1Lenalidomide 1Ketamine 1Inosine Monophosphate 1Hydromorphone 1Glucose 1Donepezil 1Cognitive Behavioral Therapy 1Buprenorphine 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cancer Pain × tanezumab × Clear all
NCT02609828 2023-02-16

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Pfizer

Phase 3 Completed
156 enrolled 31 charts
Plasma cell

Cancer Pain, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡